Literature DB >> 10796987

Avidin and streptavidin in clinical diagnostics.

H Schetters1.   

Abstract

With the introduction of the SA/Bi technology into the clinical diagnostic field ultrasensitive tests with an acceptable turn-around time became feasible. Cytokine ELISAs with lower detection limit in the picogram range became finally available. Prior to the introduction of SA/Bi only elevated levels of target could be detected by short time tests but not the normal base level. The turn around time for standard clinical immunological tests was reduced to 10-20 min from 2-4 h in old assays.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10796987     DOI: 10.1016/s1050-3862(99)00034-0

Source DB:  PubMed          Journal:  Biomol Eng        ISSN: 1389-0344


  5 in total

1.  Thermal and sodium dodecylsulfate induced transitions of streptavidin.

Authors:  Mark J Waner; Irina Navrotskaya; Amanda Bain; Edward Davis Oldham; David P Mascotti
Journal:  Biophys J       Date:  2004-08-06       Impact factor: 4.033

2.  Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera.

Authors:  Gaurav Batra; Satish K Nemani; Poornima Tyagi; Sathyamangalam Swaminathan; Navin Khanna
Journal:  BMC Infect Dis       Date:  2011-03-15       Impact factor: 3.090

3.  Biotin-tagged proteins: Reagents for efficient ELISA-based serodiagnosis and phage display-based affinity selection.

Authors:  Vaishali Verma; Charanpreet Kaur; Payal Grover; Amita Gupta; Vijay K Chaudhary
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

4.  Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen.

Authors:  Hao Hong; Jiangtao Sun; Weibo Cai
Journal:  Biomark Insights       Date:  2008-09-23

Review 5.  Recent Advances in Electrochemical and Optical Biosensors Designed for Detection of Interleukin 6.

Authors:  Munezza Ata Khan; Mohammad Mujahid
Journal:  Sensors (Basel)       Date:  2020-01-23       Impact factor: 3.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.